Nitric oxide inhibits human rhinovirus-induced transcriptional activation of CXCL10 in airway epithelial cells

J Allergy Clin Immunol. 2009 Jan;123(1):201-208.e9. doi: 10.1016/j.jaci.2008.09.041. Epub 2008 Nov 4.

Abstract

Background: Human rhinovirus (HRV) infections trigger exacerbations of asthma and chronic obstructive pulmonary disease. Nitric oxide (NO) inhibits HRV replication in human airway epithelial cells and suppresses HRV-induced epithelial production of several cytokines and chemokines.

Objective: We sought to delineate the mechanisms by which NO inhibits HRV-induced epithelial production of CXCL10, a chemoattractant for type 1 T cells and natural killer cells.

Methods: Primary human bronchial epithelial cells or cells of the BEAS-2B human bronchial epithelial cell line were exposed to HRV-16 in the presence or absence of the NO donor 3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine (PAPA NONOate). A cGMP analogue and an inhibitor of soluble guanylyl cyclase were used to examine the role of the cyclic guanosine monophosphate (cGMP) pathway in the actions of NO. BEAS-2B cells were transfected with CXCL10 promoter-luciferase constructs and the effects of PAPA NONOate were examined to study mechanisms of transcriptional regulation. Electrophoretic mobility shift assays were also used.

Results: PAPA NONOate inhibited HRV-16-induced increases in CXCL10 mRNA and protein. Inhibition of CXCL10 production occurred through a cGMP-independent pathway. PAPA NONOate inhibited HRV-16-induced CXCL10 transcription by blocking nuclear translocation, binding, or both of both nuclear factor kappaB and IFN response factors (IRFs) to their respective recognition elements in the CXCL10 promoter.

Conclusions: NO inhibits HRV-16-induced production of CXCL10 by inhibiting viral activation of nuclear factor kappaB and of IRFs, including IRF-1, through a cGMP-independent pathway. The broad-ranging inhibition of HRV-induced epithelial cytokine and chemokine production by NO suggests a potential therapeutic utility of NO donors in viral exacerbations of asthma and chronic obstructive pulmonary disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Active Transport, Cell Nucleus / immunology
  • Asthma / immunology
  • Cell Line
  • Cell Nucleus / immunology
  • Cell Nucleus / metabolism
  • Chemokine CXCL10 / biosynthesis
  • Chemokine CXCL10 / immunology*
  • Cyclic GMP / immunology
  • Cyclic GMP / metabolism
  • Epithelial Cells / immunology*
  • Epithelial Cells / metabolism
  • Epithelial Cells / virology
  • Humans
  • Hydrazines / pharmacology
  • Hydrazines / therapeutic use
  • Interferon Regulatory Factor-1 / immunology
  • Interferon Regulatory Factor-1 / metabolism
  • NF-kappa B / immunology
  • NF-kappa B / metabolism
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / immunology
  • Nitric Oxide / pharmacology
  • Nitric Oxide / therapeutic use
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Donors / therapeutic use
  • Picornaviridae Infections / drug therapy
  • Picornaviridae Infections / immunology*
  • Picornaviridae Infections / metabolism
  • Respiratory Mucosa / immunology*
  • Respiratory Mucosa / virology
  • Response Elements / immunology
  • Rhinovirus / immunology*
  • Rhinovirus / metabolism
  • Transcription, Genetic / drug effects
  • Transcription, Genetic / immunology
  • Transcriptional Activation / drug effects
  • Transcriptional Activation / immunology*
  • Virus Activation / drug effects
  • Virus Activation / immunology

Substances

  • CXCL10 protein, human
  • Chemokine CXCL10
  • Hydrazines
  • Interferon Regulatory Factor-1
  • NF-kappa B
  • Nitric Oxide Donors
  • PAPA NONOate
  • Nitric Oxide
  • Cyclic GMP